THE EUROPEAN CANNABIS OPPORTUNITY

EU MARKET SIZE 2019

EU Market Share

There are three main categories of cannabis.

Medicinal:

a) Medical
Cannabinoid-based medicine not holding marketing authorisation and therefore sold as an unlicensed medicine that is supplied through health systems and prescribed by a doctor;
or
Active Pharmaceutical Ingredients (API) to be manipulated and/or compounded by a magistral pharmacy in order to prepare a cannabinoid-based medicine without marketing authorisation (unlicensed).

b) Pharmaceutical Cannabis
Refers to products that have been through clinical trials and licensed as medicine.

CBD and other “over the counter” cannabinoids

CBD is a non-psychoactive chemical entity found in cannabis, that is recently being accepted as safe. CBD is deployed in many over the counter (OTC) products. There are other cannabinoids, terpenes etc. that are considered safe and also deployed into OTC products.

Adult Use/ Recreational
Recreational cannabis is any cannabis used for non-medical purposes, and typically has a higher concentration of THC – the chemical compound that provides the user a “high”. CBD products are used for “wellness purposes” such as sleep and anxiety and do not require a prescription.

With a population of more than double that of the United States and Canada combined, Europe is set to become the world’s largest legal cannabis market and could be worth as much as €123 billion by 2028 according to researchers at Prohibition Partners in a report titled “The European Cannabis Report”.

The UK is AltoVerde’s initial focus as it is the largest one of the largest  consumer markets in Europe. 

WHY ALTOVERDE?

Why Altoverde?

OUR GOAL

CBD BUSINESS MODEL

EU CBD MARKET SHARE

2021 – €1.25 Billion
2022 – €1.47 Billion
2023 – €1.50 Billion
2024 – €1.55 Billion
2025 – €1.65 Billion

ALTOVERDE's ROUTE TO 1%(CBD) MARKET SHARE in 2025

2021 – 0.07%
2022 – 0.20%
2023 – 0.50%
2024 – 0.70%
2025 – 1.00%

TOTAL REVENUE

€41.7M

BUSINESS OBJECTIVES

  1. Generate sufficient initial profit in the first year of operations through the wholesale distribution of AltoVerde’s very attractively priced CBD to support the creation of an extraction facility, laboratories and grow ops in UK or EU.

  2. To import AltoVerde medicinal cannabis and formulations for patient offerings via Private Clinics.

  3. Capture a share of the medicinal cannabis market by releasing licensed medicines through a pharmaceutical company joint venture following successful Research & Development and Clinical Trials.

FUNDRAISING INFO

1

Seed Rounds
2021

2

2022 Funding Round tbc

3

3rd Funding round tbc. 

DON'T MISS
THE OPPORTUNITY

INVESTOR ENQUIRIES

Are you a potential investor, interested to learn more? Please use the form below to get in touch.

For any other enquiries please use our Contact Form.